Continuous Glucose Monitoring in Older In-patients with Type 2 Diabetes and Cognitive Impairment – A feasibility study

Busra Donat Ergin, M.Sc.[1], Katharina Mattishent, Ph. D[1,2], Anne-Marie Minihane Ph.D.[1], Richard Holt Ph.D. [3], Helen R. Murphy MD. [1,2], Ketan Dhatariya, Ph.D.[1,2], Michael Hornberger, Ph.D.[3]

Author Affiliations: [1] Norwich Medical School, University of East Anglia, NR4 7TJ, Norwich, United Kingdom, [2] Norfolk & Norwich University Hospital, Norwich, United Kingdom, [3] Faculty of Medicine, University of Southampton, Southampton, United Kingdom.

Abstract

Background: Type 2 diabetes (T2DM) and cognitive impairment are common chronic conditions affecting older people in hospital. Cognitive impairment can complicate glucose monitoring and lead to diabetes-related emergencies in T2DM. Traditionally, point of care test (POCT) measurements of blood glucose are conducted in-hospital for T2DM while continuous glucose monitoring (CGM) is not widely used.

Aim: To understand the feasibility, acceptability and tolerability of using CGM in older in-patients with T2DM and cognitive impairment.

Methods: Thirty-two older people (mean age = 78.7 ±6.7) with comorbid T2DM and cognitive impairment (AMT ≤8/10 and Mini-ACE ≤22/30) were recruited within a tertiary care hospital in the UK. All participants were naive to CGM and were asked to wear blinded Dexcom G7 sensors for up to 10 days. Participants were asked feasibility, acceptability and tolerability questions at the point of sensor removal.

Results: Twenty-nine participants (96%) reported no pain during CGM fitting. All participants (100%) agreed that they did not feel the sensor, and it did not affect their day-to-day hospital activities. All participants (100%) answered 'very easy' or 'easy' for having the sensor fitted and wearing it for 10 days, with 27 participants (90%) finding CGM convenient. Seventeen participants (56.6%) reported that they were encouraged to use CGM in the future.

Conclusion: CGM use in older in-patients with T2DM and cognitive impairment is highly feasible and acceptable for patients. Future studies and trials are now needed to evaluate the clinical use of CGM for glucose monitoring in hospitalised or community-dwelling older individuals with T2DM and cognitive impairment.

Keywords: Continuous glucose monitoring, Hospitalization, Dementia, Inpatients

Corresponding Author: Michael Hornberger, Clinical Neurosciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.; Email: M.hornberger@soton.ac.uk

Funding Source: None.

Conflict-of-Interest Disclosure: None.

Acknowledgements: None.

Introduction

Type 2 diabetes (T2DM) is a common chronic condition associated with a loss of insulin sensitivity and hyperglycaemia mostly affecting adults, particularly older adults. Individuals aged 65 years and older with T2DM constitute nearly half of the total population of all age groups diagnosed with all types of diabetes mellitus [1].

Chronic complications of diabetes increase with the duration of disease and can lead to disability, lower quality of life and eventually higher mortality. While the most common chronic complications are cardiovascular diseases, gangrene and stroke [2], one of the long-term common complications of diabetes is dementia [3]. Diabetes significantly increases dementia risk, particularly with longer diabetes duration or presence of hypoglycaemia [4]. This cognitive impairment emerges through complex interactions involving insulin resistance, brain hypometabolism, inflammatory processes, vascular injury, and reduced cerebral blood flow, and oxidative stress [5].

Cognitive impairment can complicate glucose monitoring, further exacerbating diabetes complications and dementia pathophysiology progression. Advances in technology for better diabetes management such as continuous glucose monitoring (CGM) can contribute to decreasing the number of complications as well as the risk of cognitive decline [2]. Recent data shows that holistic and individualised approach is the ideal approach for diabetes treatment for older adults with a variety of comorbidities with T2DM [6]. CGM is emerging as a valuable technology due to its safety and practicality, particularly for individuals with multimorbidity or geriatric syndromes such as cognitive impairment [7]. However, more research is needed to understand the benefits and challenges of CGM in this population with T2DM and cognitive impairment.

Traditionally, point of care test (POCT) measurements of blood glucose are conducted in-hospital for T2DM whilst continuous glucose monitoring (CGM) is not currently used in the wards since there is no established feasibility of using such devices within the hospital[8]. This feasibility study aims to investigate the feasibility, acceptability and tolerability of CGM in older adults with T2DM and cognitive impairment while being in-patients.

Methodology

Study Design

A mixed-method observational feasibility study of CGM among older people with T2DM and cognitive impairment who are in-hospital patients.

Participants: Inclusion and Exclusion Criteria

Eligible participants were older (≥65 years) individuals with T2DM for at least 6 months and who were in-patients on diabetes management medications (i.e. managed not only by diet/lifestyle). Participants were also required to have an Abbreviated Mini-Mental Test (AMT) score equal or less than 8 (out of 10) and/ or a Mini-Addenbrooke's Cognitive Examination (Mini-ACE) UK Version A score ≤21 (out of 30), indicating cognitive impairment. The AMT is commonly used, brief cognitive screening tool within hospitals in the UK. The Mini-ACE is a cognitive screening tool sensitive to earlier cognitive changes using two cut-offs (25 or 21 out of 30) [10], and has been validated in various settings.

Potential participants were excluded if they did not have mental capacity and/or were on end-of-life care, as confirmed by the clinical care teams. We also excluded people who were current CGM users, were undergoing dialysis treatment and showed evidence of skin irritations on the upper arm or abdomen where the CGM sensor would potentially be fitted. We also excluded people who had other neurological or psychiatric diseases, as well as those with autism, dyslexia or learning difficulties.

Setting

Data collection took place in a tertiary care hospital in England (Norfolk and Norwich University Hospitals NHS Foundation Trust) and the CGM sensor was fitted whilst the consented participants were in-patients (as detailed in the recruitment process section).

Device choice

We used the Dexcom G7 CGM device which is licensed for use in children and adults and available for consumers to directly purchase. The kits consist of auto applicator kits with sensors with transmitter and receivers to be used in the blind mode. We provided blinded receivers to all participants and clinical staff which was paired with their sensors in advance.

The sensors were applied to the back of the upper arm. Interstitial glucose readings were measured continuously, and data was transmitted from the sensor every 5 minutes. Time in range (TIR) was established, using a range set between 4 mmol/L to 10 mmol/L in the receiver, which was the default setting, and similar to recommendations [11], [12], [13].

The CGM manufacturer (Dexcom Inc, San Diego, USA) donated half of the sensor kits.

Recruitment process

One of the study members investigated the initial selection of potential participants via the hospital electronical system (Integrated Clinical Environment: ICE) by checking admissions according to the inclusion criteria, except eligibility criteria of AMT and Mini-ACE, and approached the potential participants with a consent to contact form. Potential participants were subsequently given the participant information sheet (PIS) and allowed 24 hours to consider taking part in the study. After 24 hours, potential participants were revisited, and if they agreed to participate were consented. After their consent, they were assessed for cognitive impairment via the AMT and Mini-ACE. If participants had a score of 8 or lower on the AMT and/or a score of 22 or lower on the Mini-ACE, they were invited to take part in the study. If the cognitive screening scores indicated no cognitive impairment, participants were told that they were not eligible for participation. Please see Figure-1 for a detailed flow chart of the recruitment process.

Participants continued to receive their usual hospital care and with their usual diabetes management during the study period.

Baseline assessment

A research team member fitted a CGM sensor on the participant's upper arm and blinded the receiver. Participants sociodemographic details (sex, age, ethnicity, marital status, smoking and driving status) were obtained.

We collected dried blood spot samples (DBS) via finger prick from all participants and stored in -80C freezers for future analyses.

Follow-up assessment

The follow-up assessment was conducted on the 10th day after CGM sensor fitting. The 10-day study period was chosen due to the manufacturers recommendation to change the sensor after 10 days and considering that some people would not be hospitalised for longer than 10 days. The participant was visited at their hospital bed or if they had been discharged, at their residence (private or care home). If the participants were discharged within 10 days, they were discharged wearing the sensor and taking the receiver, before a research team member removed the sensor on the 10th day and uploaded the data to Dexcom Clarity® system anonymously. The participants were asked CGM feasibility, acceptability and tolerability questions via a questionnaire, including open-ended questions. Finally, participants underwent the same cognitive testing as during the first research appointment and a further DBS sample was collected. Clinical data for all participants was collected via the hospital's electronical clinical care management system.

CGM feasibility-acceptability and tolerability survey

Feasibility, acceptability and tolerability were determined via a questionnaire (see Appendix-1), including 1 pain scoring question, 2 dichotomous, 7 Likert-style multiple choice questions, and 2 open-ended questions. We encouraged participants to talk about their experiences and additional thoughts about the device with open-ended questions. The questionnaire was modified from a previous CGM feasibility study [14].

Results

A total of 32 participants were recruited, with the final sample comprising 30 participants. We excluded 2 participants: one due to more than 50% missing CGM readings during the 10-day study period; and the second because they were not taking antidiabetic medication.

1. *Sociodemographic characteristics*

The mean age was 78.76 ± 6.71 years, with 18 male (60%) and 12 female (40%) participants. 13 participants (43.3%) were living alone, whilst the remainder were living with a partner, child, grandchildren or in a care home (n=2, 6.6%). All participants were retired. Two thirds were secondary school graduates, with 6 (20%) having a higher education degree (Bachelor's or higher) and 5 (16.6%) did not finish high school.

Table-1: Participant Characteristics

Participant characteristics	Mean	Min	Max
Age (years) $\pm$ SD	78.7 ± 6.7	67	94
BMI (kg/cm^2) $\pm$ SD	31.2 ± 10.9	20.7	74.3
HbA1c (mmol/mol) $\pm$ SD	75.1 ± 29.5	45	154
Medications (N)	10.5 ± 4.4	3	20
Hospitalisations (N) in the last 12 months (excluding the time of recruitment)	0.8 ± 1.5	0	8
Length of T2DM (Years)	14.9 ± 6.4	0.6	38

Only 5 participants (16.6%) were walking for pleasure or shopping with 3 out of the 5 walking less than 1 hour per week. Seven participants (23.3%) were doing light housework such as cooking and cleaning for less than 3 hours/week and eight (26.6%) were doing gardening or do-it-yourself (DIY) activities. 43.3% were sedentary; however, ten participants had at least one leg ulcer, lower limb cellulitis or diabetic foot, and two had leg amputation which affected physical activity levels. The mean frailty score among our participants was 5.83 ± 0.83 (using 1-9 scale, fitness vs. vulnerability), which indicates that the majority of them were mildly frail.

2. *Feasibility, tolerability and acceptability outcomes*

Twenty-nine participants (96%) reported no pain during CGM fitting. All participants agreed that they did not feel the sensor once fitted, and it did not affect their day-to-day hospital activities. All participants answered 'very easy' or 'easy' for having the sensor fitted and wearing it for 10 days, with 27 participants (90%) finding CGM convenient. Seventeen participants (56.6%) reported that they were encouraged to use CGM in the future.

Most participants reported that they forgot the sensor's existence and did not feel anything, and it was easy to keep CGM for 10 days ($\geq$73.3%). Two participants agreed that they would prefer to use CGM compared to POCT in their daily life since they had sore fingers and numbness and found it painful to prick their fingers multiple times a day. Three participants

(10%) reported that they needed to remind healthcare staff that they were wearing a CGM sensor, when they were measuring blood pressure via upper arm blood pressure cuffs. One participant (3.3%) reported that the sensor came off on the 4th day, and that they did not wish to have a replacement sensor.

Three participants (10%) said they were happy to contribute to the research, as diabetes and dementia are very serious diseases and research in this field should be encouraged. One participant who had low nocturnal sensor reading commented "*It was good to see hypo readings during the night; I was not aware that I am having it frequently. But I knew it decreases sometimes. I will inform my diabetes nurse and GP about it and discuss CGM, my current medications and night-time snacks*".

3. *CGM vs POCT readings*

Mean time in range (TIR= 4-10 mmol/mol) was 36.2%, time above range (TAR >= 10 mmol/mol) was 62.8% and time below range (TBR <= 3.9 mmol/mol) was 1% (Table-1). Fourteen (46.6%) participants wore their CGM continuously in hospital, with CGM active for 89.9% of the time (min= 86%, max= 95%).

Table-2: CGM and POCT metrics

Metrics	Mean		Min		Max	
	CGM	**POCT**	**CGM**	**POCT**	**CGM**	**POCT**
Measurements/ day (N)	285	4.8	260	2.5	288	9
Glucose (mmol/L)	12.5	12.4	<2.2*	2.1	>22.2**	>33.3**
CV (%)	39.7	62.7	15.5	14.5	47.4	57.8
SD	5.0	7.8	1.8	1.6	6.1	8.3
TIR (%)	36.2	40.8	0	0	90	92.5
TAR (%)	62.8	57.2	8	3.5	100	100
TBR (%)	1	1.8	0	0	9	12.8

* Lower measurement limit of CGM.
** Upper measurement limits of CGM and POCT.

Overall, CGM data was very similar and consistent to POCT glucose measurements (Table-2). One participant (3.3%) had an apparent CGM sensor fault at day 6 after sensor fitting, leading to consistent above range readings compared to POCT. For this participant, we only included CGM data up to day 6.

4. Clinical data

Six (30%) were admitted as in-patients due to diabetes related issues (e.g. DKA, hypoglycaemia, hyperosmolar hyperglycaemic state (HHS). Another third was admitted due to a fall, either due to hypoglycemic or other reasons. One was admitted due to cognitive impairment and confusion. Twenty-four (80%) participants had at least four comorbidities at admission.

One participant had a diagnosis of dementia, which was Lewy body dementia, for 1 year. At the second research appointment, fourteen participants (46.6%) were still in hospital, including two (6.6%) at a different hospital for rehabilitation. Two participants (6.6%) were discharged to care home or nursing home, while fourteen (46.6%) were at their private home at the end of the study.

Table-3: Medication classes

Diabetic Medications	Total Number of participants N (%)
Insulin	9 (30%)
Metformin	16 (53.3%)
SGLT-2 inhibitors	9 (30%)
DPP4 inhibitors	4 (13.3%)
Sulphonylurea	3 (10%)
GLP-1 agonists	1 (3.3%)
Commonly prescribed other medications	
Statins	20 (66.6%)
Anticoagulants/Antiplatelets	20 (66.6%)
Topical agents	17 (56.6%)
Analgesics	15 (50%)
Antibiotics	8 (26.6%)

Thirty percent of participants were treated with insulin, while 46.6% were on oral glucose lowering agents, and 30% of the participants were using both insulin and oral agents (Table-3). Due to diabetic foot or foot ulcers, 56.6% were regularly using topical agents. Supplements and multivitamins (mostly vitamin D, folic acid and thiamine) were commonly used (73.3%).

5. Cognitive Status

All participants completed the cognitive tests after fitting CGM in the first research appointment. The participants were screened with AMT and Mini-ACE to decide their eligibility for this study. The mean AMT of the participants was 7.2 ± 2.2 and the mean Mini-ACE was 15.6 ± 4.1. We also compared AMT and Mini-ACE scores before and after using CGM using paired t-test analyses (n=28). There was no significant difference in AMT scores (p=0.28), while Mini-ACE scores increased significantly (p<0.01), indicating cognitive improvement. Results of our study demonstrate how cognitive impairment common in this frail population, despite the absence of a formal dementia diagnosis.

Table-4: Cognitive Assessment

Cognitive Tests	Mean	Min	Max
AMT (baseline assessment) ± SD	7.2 ± 2.2	3	10
Mini-ACE (baseline assessment) ± SD	15.6 ± 4.1	5	22
AMT (follow up assessment*) ± SD	7.5 ± 2.1	3	10
Mini-ACE (follow up assessment*) ± SD	18.5 ± 4.9	8	26

2 participants (6.6%) did not complete the cognitive testing at the follow up appointment; 1 participant reported they were feeling unwell due to diabetic foot pain and did not wish to do cognitive tests, whilst the other participant was transferred from their ward to critical care unit.

Overall, the results showed high feasibility and acceptability among in-patients with T2DM and cognitive impairment.

Discussion

Our study suggests that CGM use is highly feasible and acceptable for older hospitalised individuals with T2DM and cognitive impairment. Specifically, the results of our study were similar to a previous CGM feasibility study in the same population within the community, i.e. not in-hospital [14]. Both their and our findings demonstrate high feasibility and acceptability of CGM. Similarly, both studies showed potential value of CGM for capturing nocturnal hypoglycaemia in those at risk. Our findings extend this to in-hospital patients with T2DM and cognitive impairment, suggesting that CGM is highly acceptable and well tolerated by participants. Moreover, participants reported that CGM did not affect day-to-day activities at the hospital.

The other promising finding was that more than half the participants were encouraged to use CGM in the future, despite not having done so previously. While TIR goal for glucose level between 70 and 180 mg/dL (3.9-10 mml/L) is >70% for the general population [15], consensus suggests less stringent thresholds for older people, with a TIR target of >50% [16]. Despite this lower TIR goal, the mean TIR in our population was still low. Lifestyle interventions such as regular physical activity, healthy and balanced diet and modest weight loss, have been recommended to improve glucose targets, however, our sample was clearly physically inactive, and many had severe diabetes related complications, including amputations, hindering their physical activity levels and increasing their frailty [17]. Further, multiple other reasons, including polypharmacy, perioperative procedures, and other hospital changes might affect the glucose readings of patients. Finally, clinical guidelines are clearly geared towards the reduction of hypoglycaemia [17], [18], which might explain the low TIR within our participants.

According to the CGM results, there were 28 hypoglycaemic events (<=3.9 mmol/L) for 9 participants. Eleven of the hypoglycaemic events (39.3%) were nocturnal (12am-6am). However, low nocturnal sensor glucose readings in our study may not directly reflect true nocturnal hypoglycaemia and should be interpreted in light of potential sensor bias and sensor–clinical discordance [19]. Previous studies suggests that CGM may show less accuracy with lower glucose ranges compared to POCT and highly recommend double-checking capillary glucose [8], [20], [21], [22].

The in-hospital setting was in itself challenging, with some potential participants finding it overwhelming to take part in our study part despite expressing initial interest. It highlights the challenges of conducting research in inpatient settings. For this reason, larger prospective studies or clinical trials are warranted to evaluate the impact of CGM within this setting and to determine the optimal clinical implementation strategies for CGM use in this vulnerable inpatient group. In this regard, it is also interesting that half of our participants considered using CGM in the future, i.e. after discharge from the hospital. This highlights another research gap, in that people within the community could benefit from CGM use. Indeed, retrospective data analyses have suggested that CGM use in T2DM and cognitive impairment in the community can affect overall mortality and hospitalisation rates [23], [24]. One is RELIEF study showing that two years use of flash glucose monitoring was associated with 49% reduced hospitalization due to acute diabetic events mainly diabetic ketoacidosis (DKA) [9]. Future prospective CGM studies in the community settings in this regard are needed urgently to reduce mortality and hospitalisation in the first place of this vulnerable group.

In terms of the cognitive screening findings, our results showed that a discrepancy between the employed cognitive measures (AMT vs Mini-ACE). The AMT is widely used to assess cognitive status in hospital settings [25]. Although it has practical use on the wards and at hospital admission, there are some limitations regarding language and culture, as well as unreliability of certain questions and reduce sensitivity to detect cognitive changes cross sectionally and longitudinally [26], [27]. Because of these limitations, we included the Mini-ACE in our cognitive screening, which is commonly used in UK memory clinics for dementia screening. Our results showed that the Mini-ACE is more sensitive and less likely to have ceiling effects than the AMT. We only applied the lower Mini-ACE cut-off (<=21/30), since this score is accepted as almost certain score for dementia or a person with cognitive impairment [28]. AMT results of potential participants were higher than Mini-ACE and would have resulted in exclusion of most potential participants. It suggests that the AMT might be not suitable to cognitively screen in hospital, as it only detects severe cognitive deficits, e.g. delirium, while potentially missing patients with mild to moderate cognitive deficits. There is a dearth of research on how cognitive impairment levels impact glucose management in older T2DM people. Our results show that despite all participants having mental capacity to consent to the research, there cognitive performance moderate cognitive impairment, further complicating diabetes management.

Interestingly, our Mini-ACE scores at the follow-up assessment were significantly higher than the baseline assessment scores. This might have been due to patients having recovered from their conditions, they were admitted for in the first place. It also highlights that cognition levels can change during hospital stays. In this regard, it was also telling that the AMT scores did not change from baseline to follow-up, further underlining that the AMT has limited sensitivity to measure cognitive impairment and changes. Future research on cognitive screening in hospital settings is needed to determine whether better tools than the AMT can be applied, as they might improve patient care, including glucose management.

To our knowledge, our study is the first CGM feasibility study in older in-patients with comorbid T2DM and cognitive impairment. Despite, the promising findings, there are some limitations to our study. Overall, this is a small pilot study, which requires replication in a larger sample and different hospital settings. Further, participants were admitted to the hospital due to different health conditions including emergencies. Therefore, they were not in their best health condition, and this might have affected the cognitive and CGM results. We ran our recruitment search in particular wards due to our inclusion criteria (older age), and having longer hospital stays. This selection may have caused a potential bias in the

recruitment process; for example, we recruited five participants from a general surgery ward which potentially resulted in lower physical activity scores in our study population since some participants were awaiting lower limb amputations. Finally, in our study, we used masked CGM, and it is, therefore, not clear whether CGM use can actually improve glucose management in hospital, compared to traditional POCT, which requires future RCTs. Based on that, future research should be considered with larger inpatient populations in the community to evaluate whether CGM use can improve glucose management and clinical outcomes compared to standard care. Additionally, exploring optimal sensor placement and training for health care professionals may enhance usability and adherence in hospital settings. Furthermore, community-based studies are needed to investigate the potential cognitive benefits associated with improved glucose variability through long-term use of unblinded CGM in this frail population.

In conclusion, CGM is highly feasible and acceptable for older hospitalised patients living with T2DM and cognitive impairment. CGM technology offers an advantage by capturing events such as asymptomatic nocturnal hypoglycaemia. Further investigation is required to understand in more detail the benefits and challenges of CGM in inpatient care for those with T2DM and cognitive impairment.

References

[1]   S. Bellary, I. Kyrou, J. E. Brown, and C. J. Bailey, "Type 2 diabetes mellitus in older adults: clinical considerations and management," *Nat Rev Endocrinol*, vol. 17, no. 9, pp. 534–548, Sep. 2021, doi: 10.1038/S41574-021-00512-2.

[2]   A. D. Deshpande, M. Harris-Hayes, and M. Schootman, "Epidemiology of Diabetes and Diabetes-Related Complications," *Phys Ther*, vol. 88, no. 11, p. 1254, Nov. 2008, doi: 10.2522/PTJ.20080020.

[3]   B. Cholerton, L. D. Baker, T. J. Montine, and S. Craft, "Type 2 Diabetes, Cognition, and Dementia in Older Adults: Toward a Precision Health Approach," *Diabetes Spectr*, vol. 29, no. 4, p. 210, Nov. 2016, doi: 10.2337/DS16-0041.

[4]   F. Cao *et al.*, "The relationship between diabetes and the dementia risk: a meta-analysis," *Diabetol Metab Syndr*, vol. 16, no. 1, p. 101, Dec. 2024, doi: 10.1186/S13098-024-01346-4.

[5]   W. Kan, M. Qu, Y. Wang, X. Zhang, and L. Xu, "A review of type 2 diabetes mellitus and cognitive impairment," *Front Endocrinol (Lausanne)*, vol. 16, p. 1624472, 2025, doi: 10.3389/FENDO.2025.1624472.

[6]   J. S. Yun, K. Kim, Y. B. Ahn, K. Han, and S. H. Ko, "Holistic and Personalized Strategies for Managing in Elderly Type 2 Diabetes Patients," *Diabetes Metab J*, vol. 48, no. 4, p. 531, Jul. 2024, doi: 10.4093/DMJ.2024.0310.

[7]   B. Donat Ergin, K. Gadsby-Davis, K. Mattishent, K. Dhatariya, N. Garner, and M. Hornberger, "Continuous Glucose Monitoring in Comorbid Dementia and Diabetes: The Evidence So Far," 2024, *SAGE Publications Inc.* doi: 10.1177/19322968241301058.

[8]   P. Avari *et al.*, "Continuous Glucose Monitoring Within Hospital: A Scoping Review and Summary of Guidelines From the Joint British Diabetes Societies for Inpatient Care," *J Diabetes Sci Technol*, vol. 17, no. 3, pp. 611–624, May 2023, doi: 10.1177/19322968221137338/ASSET/A90AB778-C539-4F63-B64D-77B83AF3ADDE/ASSETS/IMAGES/LARGE/10.1177_19322968221137338-FIG2.JPG.

[9]   J. P. Riveline *et al.*, "Reduced Rate of Acute Diabetes Events with Flash Glucose Monitoring Is Sustained for 2 Years After Initiation: Extended Outcomes from the RELIEF Study," *Diabetes Technol Ther*, vol. 24, no. 9, pp. 611–618, Sep. 2022, doi: 10.1089/DIA.2022.0085.

[10]   S. Hsieh *et al.*, "The mini-addenbrooke's cognitive examination: A new assessment tool for dementia," *Dement Geriatr Cogn Disord*, vol. 39, pp. 1–11, Feb. 2015, doi: 10.1159/000366040.

[11]   T. Battelino *et al.*, "Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range," *Diabetes Care*, vol. 42, no. 8, pp. 1593–1603, Aug. 2019, doi: 10.2337/DCI19-0028.

[12]   T. Danne *et al.*, "International consensus on use of continuous glucose monitoring," *Diabetes Care*, vol. 40, no. 12, pp. 1631–1640, Dec. 2017, doi: 10.2337/DC17-1600/-/DC1.

[13]   E. G. Wilmot *et al.*, "Time in range: A best practice guide for UK diabetes healthcare professionals in the context of the COVID 19 global pandemic," *Diabetic Medicine*, vol. 38, no. 1, p. e14433, Jan. 2020, doi: 10.1111/DME.14433.

[14]   K. Mattishent *et al.*, "Continuous glucose monitoring in older people with diabetes and memory problems: A mixed-methods feasibility study in the UK," *BMJ Open*, vol. 9, no. 11, Nov. 2019, doi: 10.1136/bmjopen-2019-032037.

[15]   T. Battelino *et al.*, "Clinical targets for continuous glucose monitoring data interpretation: Recommendations from the international consensus on time in range," *Diabetes Care*, vol. 42, no. 8, pp. 1593–1603, Aug. 2019, doi: 10.2337/dci19-0028.

[16]   E. Toschi, D. O'Neal, M. Munshi, and A. Jenkins, "Glucose Targets Using Continuous Glucose Monitoring Metrics in Older Adults With Diabetes: Are We There Yet?," *J Diabetes Sci Technol*, vol. 18, no. 4, pp. 808–818, Jul. 2024, doi: 10.1177/19322968241247568.

[17]   "13. Older Adults: Standards of Care in Diabetes—2024," *Diabetes Care*, vol. 47, pp. S244–S257, Jan. 2024, doi: 10.2337/dc24-S013.

[18]   P. Avari *et al.*, "Continuous Glucose Monitoring Within Hospital: A Scoping Review and Summary of Guidelines From the Joint British Diabetes Societies for Inpatient Care," *J Diabetes Sci Technol*, vol. 17, no. 3, pp. 611–624, May 2023, doi: 10.1177/19322968221137338.

[19]   C. Bay, P. L. Kristensen, U. Pedersen-Bjergaard, L. Tarnow, and B. Thorsteinsson, "Nocturnal Continuous Glucose Monitoring: Accuracy and Reliability of Hypoglycemia Detection in Patients with Type 1 Diabetes at High Risk of Severe Hypoglycemia," *https://home.liebertpub.com/dia*, vol. 15, no. 5, pp. 371–377, May 2013, doi: 10.1089/DIA.2013.0004.

[20]   L. Vu *et al.*, "Predicting Nocturnal Hypoglycemia from Continuous Glucose Monitoring Data with Extended Prediction Horizon," *AMIA Annual Symposium Proceedings*, vol. 2019, p. 874, 2020, Accessed: Jan. 07, 2026. [Online]. Available: https://pmc.ncbi.nlm.nih.gov/articles/PMC7153099/

[21]   S. K. Garg *et al.*, "Accuracy and Safety of Dexcom G7 Continuous Glucose Monitoring in Adults with Diabetes", doi: 10.1089/dia.2022.0011.

[22]   E. Gamarra, G. Careddu, A. Fazi, V. Turra, A. Morelli, and P. Trimboli, "Calibrating Dexcom G7 improves its performance in the context of repetitive recreational scuba diving in people with type 1 diabetes," *BMJ Open Sp Ex Med*, vol. 11, p. 2809, 2025, doi: 10.1136/bmjsem-2025-002809.

[23]   P. Kotecha, S. M. Smith, W. T. Donahoo, S. T. DeKosky, J. Bian, and J. Guo, "Continuous Glucose Monitoring in Insulin-Treated Older Adults With Diabetes and Alzheimer Disease and Related Dementias," *JAMA Netw Open*, vol. 8, no. 12, p. e2541939, Dec. 2025, doi: 10.1001/JAMANETWORKOPEN.2025.41939.

[24]   P. D. Reaven *et al.*, "Initiation of Continuous Glucose Monitoring and Mortality in Type 2 Diabetes," *Diabetes Technol Ther*, vol. 27, no. 10, 2025, doi: 10.1089/DIA.2025.0227.

[25]   K. Piotrowicz *et al.*, "The comparison of the 1972 Hodkinson's Abbreviated Mental Test Score (AMTS) and its variants in screening for cognitive impairment," *Aging Clin Exp Res*, vol. 31, no. 4, pp. 561–566, Apr. 2019, doi: 10.1007/s40520-018-1009-7.

[26]   A. Emery, J. Wells, S. P. Klaus, M. Mather, A. Pessoa, and S. T. Pendlebury, "Underestimation of Cognitive Impairment in Older Inpatients by the Abbreviated Mental Test Score versus the Montreal Cognitive Assessment: Cross-Sectional Observational Study," *Dement Geriatr Cogn Dis Extra*, vol. 10, no. 3, pp. 205–215, Sep. 2020, doi: 10.1159/000509357.

[27]   K. A. Peters, T. J. Howe, D. Rossiter, K. J. Hutchinson, and P. A. Rosell, "The Abbreviated Mental Test Score; Is There a Need for a Contemporaneous Update?," *Geriatr Orthop Surg Rehabil*, vol. 12, 2021, doi: 10.1177/21514593211001047.

[28]   S. Hsieh *et al.*, "The mini-addenbrooke's cognitive examination: A new assessment tool for dementia," *Dement Geriatr Cogn Disord*, vol. 39, pp. 1–11, Feb. 2015, doi: 10.1159/000366040.

Appendix

Figure-1: Participant Recruitment Process